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Introduction
Osteonecrosis or avascular necrosis (AVN) is deﬁ ned as a 
pathologic process  that  results from a critical reduction 
of blood supply to the bone and elevated intraosseous 
pressure. Although the pathogenic process is poorly 
understood, osteonecrosis is the ﬁ nal common pathway 
of traumatic and non-traumatic insults and compromises 
the already precarious circulation of the femoral head. 
Femoral head ischemia subsequently leads to the death of 
bone marrow and osteocytes and usually results in the 
collapse of the necrotic segment [1]. AVN is a debilitating 
disease that usually leads to osteoarthritis of the hip joint 
in young adults. Th e disease prevalence is unknown, but 
estimates indicate that 10,000 to 20,000 new cases are 
diagnosed in the US each year. Furthermore, it is esti-
mated that 5% to 18% of the more than 500,000 total hip 
arthroplasties performed annually are related to advanced 
AVN [2]. Joint-preserving techniques such as core de-
com pression, avascular or vascularized bone graft ing, 
and various femoral osteotomies are most promising in 
early stages of AVN – Association Research Circulation 
Osseous (ARCO) stage I and II – with preserved 
structural integrity of the subchondral plate [2]. Th e 
structural collapse of the osteonecrotic segment (ARCO 
stage III and IV) indicates the progressive course of the 
disease, and total hip replacement is inevitable in most 
cases in the long term [1,3].
Cell-based strategies
To enhance osseous regeneration, the application of 
osteogenic or angiogenic precursor cells (or both) in 
combination with or without supporting growth factors 
is an appealing possibility. Among the various cell types, 
adult tissue-derived, multipotent mesenchymal stem cells 
(MSCs) represent a highly promising candidate for cell-
based therapeutic approaches [4]. Th ese somatic adult 
stem cells can be detected in speciﬁ c tissue compart-
ments of the human body and are considered to play a 
critical role in maintaining the integrity of diﬀ erent 
tissues such as skin, bone, and blood [5]. MSCs maintain 
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the ability of mitotic multiplication without signiﬁ cant 
loss of their speciﬁ c biomolecular characteristics over 
extensive population expansion and are capable of diﬀ er-
en tiating into multiple mesenchymal phenotypes, includ-
ing osteoblasts, chondrocytes, and adipocytes [5]. MSCs 
have been shown to enhance tissue regeneration after 
transplantation in an experimental AVN model in dogs 
[6]. However, whether the observed eﬀ ects resulted from 
the osteogenic diﬀ erentiation of transplanted cells or are 
mediated via their trophic activities remains unclear 
[6,7].
Proper vascularization is essential for the viability and 
function of the majority of tissues in the body. Without 
suﬃ  cient blood supply, cells suﬀ er from hypoxia, lack of 
nutrients, and the accumulation of waste products, and 
biochemical signaling mechanisms are disrupted, aﬀ ect-
ing tissue homeostasis and preventing tissue regenera-
tion. Endothelial progenitor cells (EPCs) are spindle-
shaped cells capable of diﬀ erentiation into a mature 
endo thelial phenotype. Th ese cells can be isolated from 
bone marrow and peripheral blood [8,9]. Th eir role in 
angiogenesis and neovascularization has been studied 
extensively, and positive eﬀ ects on blood vessel formation 
after transplantation have been reported [10]. So far, 
however, these cells have not been applied clinically for 
the treatment of AVN.
Interestingly, Feng and colleagues [9] recently reported 
signiﬁ cantly decreased numbers of circulating EPCs and 
colony-forming units (CFUs) in patients with diagnosed 
AVN in comparison with a healthy control group. Further-
more, EPCs of patients with AVN exhibited impaired 
migratory capacities and increased cellular senescence, 
resulting in reduced angiogenesis in vitro [9].
Application of concentrated bone marrow aspirates
Hernigou and colleagues [11-13] pioneered the clinical 
application of a cell-based strategy for the treatment of 
AVN, percutaneously injecting an autologous bone 
marrow concentrate into the necrotic area of femoral 
heads. Th e strategy is driven by the hypothesis that 
injected bone marrow cells can repopulate the trabecular 
bone structure and subsequently revitalize and remodel 
the necrotic bone. For this technique, a bone marrow 
aspirate is harvested from the iliac crest and the 
mononuclear cell fraction is isolated. After core decom-
pression, the cell suspension is injected into the necrotic 
area [11-13]. Th ese authors reported on the postoperative 
outcome in 189 cases (116 patients) treated with the 
injection of autologous bone marrow concentrate [11]. 
Over the course of the 5- to 10-year follow-up, nine out 
of 145 patients with early-stage AVN (Steinberg stage I or 
II) and 25 out of 45 patients with later-stage AVN 
(Steinberg stage III or IV) required total hip replacement. 
However, since no control group was examined, the 
beneﬁ cial eﬀ ect of the injected bone marrow concentrate 
(that is, in comparison with sole core decompression) is 
diﬃ  cult to prove. Gangji and Hauzeur [14] conducted a 
controlled prospective study comparing the postoperative 
outcome of core decompression with core decompression 
followed by the injection of a bone marrow concentrate 
in early-stage AVN (ARCO stage I or II). Th e mean 
follow-up was 2 years, and ﬁ ve out of eight hip joints in 
the control group showed radiographic progression. In 
contrast, only one out of 10 hips treated with bone 
marrow cells progressed to a more severe stage with 
collapse of the subchondral bone [14]. Recently, Gangji 
and colleagues [15] reported on the 5-year follow-up of 
19 patients (24 hip joints) who received either core 
decompression alone or core decom pression with the 
additional application of bone marrow concentrate 
because of early-stage AVN. In this prospective, double-
blinded trial, eight out of 11 hip joints in the core 
decompression group and only three out of 13 joints in 
the bone marrow concentrate group revealed a disease 
progression with structural disintegra tion of the sub-
chondral bone [15]. Despite the promising results, the 
clinical value of these studies is limited because of short-
term follow-up periods and low case numbers.
Application of ex vivo expanded autologous bone marrow-
derived stem cells
Th e ex vivo ampliﬁ cation and further administration of 
MSCs, in contrast to bone marrow cell concentrates, are 
controlled by regulatory authorities, namely the US Food 
and Drug Administration (FDA) and the European Medi-
cines Agency (EMA) [16]. In most cases, the selec tion of 
MSCs is achieved by cell adherence to tissue culture plastic 
after phase gradient separation (that is, Ficoll or Percoll).
Th e therapeutic potential of ex vivo ampliﬁ ed bone 
marrow-derived MSCs for the treatment of cortico-
steroid-induced AVN in femoral condyles was investi-
gated by Müller and colleagues [17]. In ﬁ ve patients, bone 
marrow aspirates were harvested from the posterior iliac 
crest and MSCs were isolated and expanded for three 
passages. Th e MSCs were resuspended in 0.1% serum 
albumin-supplemented saline and transplanted into the 
necrotic area. After a mean follow-up of 16 months, none 
of the patients showed signs of disease progression. 
Owing to the lack of a control group, whether this eﬀ ect 
can be attributed to the injected cells is unclear.
Apart from cell delivery in suspension, a variety of 
matrices, such as ceramics, collagen sponges, hydrogels, 
and biodegradable polymers, have been used for cell 
delivery [4]. Core decompression oﬀ ers the opportunity 
to deliver such cell-laden biomaterials to the necrotic 
area. Concurrently with tissue neoformation, scaﬀ olds 
ideally undergo degradation processes resulting in bio-
compatible, metabolisable, and excretable by-products. 
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Speciﬁ cally, for the treatment of AVN, autologous or 
allogenic bone grafts (demineralized bone matrix, or 
DBM) as well as synthetic biomaterials (that is, beta-
tricalcium phosphate, or β-TCP) have been suggested as 
suitable carriers for cell-based strategies [3,4].
Kawate and colleagues [18] reported the treatment of 
three patients with advanced stages of cortisone-induced 
AVN (Steinberg stage III or IV) with a vascularized 
ﬁ bular graft combined with a synthetic β-TCP ceramic 
and bone marrow-derived MSCs. Four weeks prior to 
elective core decompression, 15  mL of bone marrow 
aspirate was taken from the iliac crest. MSCs were 
isolated and expanded in autologous serum. After 
10 days, MSCs were seeded onto the β-TCP granula and 
cultured for 2  weeks. After core decompression, the 
defect was ﬁ lled with the MSC-seeded β-TCP granula 
and a vascularized ﬁ bular graft was transplanted. During 
the 34-month follow-up, no progression of the AVN was 
reported [18]. Given the advanced stages treated and the 
cortisone-related genesis of the necrosis (both of which 
have been shown to lead to a decreased therapeutic 
response in general [3,19]), these results are promising. 
However, only a small number of patients were treated 
and a control group was not included.
A similar approach to treat AVN with autologous 
stromal cell-seeded β-TCP granula was presented by our 
group [20]. Th e applied cells consisted of a mixture of 
MSCs and endothelial and hematopoietic progenitor cells 
(Tissue Repair Cells, or TRC; Aastrom Biosciences, Inc., 
Ann Arbor, MI, USA).
Brieﬂ y, bone marrow aspirates (100 mL) were harvested 
bilaterally from the posterior iliac crest. Th e aspirates 
were expanded for 12 days in autologous serum-supple-
mented medium by means of a good manufacturing 
practice (GMP) system (Aastrom Biosciences, Inc.). 
Fluores cence-activated cell sorting analysis of the ex-
pand ed cells showed a signiﬁ cantly higher number of 
CFU-ﬁ broblasts and cells expressing surface markers 
characteristic of MSCs (that is, CD90) and hematopoietic 
(that is, CD133) and endothelial (that is, CD90) 
progenitor cells when compared with the mononuclear 
fraction of native bone marrow aspirates, indicating an 
enrichment of these cell types [20]. Early AVN (ARCO 
stage II) was diagnosed in all treated patients. After 
surgical exposure of the proximal femur, a bone plug was 
removed by using a hollow diamond drill. For the 
treatment of small AVN lesions (ARCO stage IIA), a K-
wire was placed centrally into the necrotic area and was 
used as a guide for a cannulated 10-mm drill bit. For the 
treatment of more extensive AVN (ARCO stage IIB and 
IIC), two drill holes were used (Figure  1A-D) [20]. 
Subsequently, β-TCP granula (Vitoss; Orthovita Inc., 
Malvern, PA, USA) were placed in a custom-made plastic 
tray and the TRC suspension was homogeneously seeded 
onto the granula (Figure  2A). For ease of handling, 
autologous plasma obtained during surgery was used to 
achieve physical bonding between the MSC-seeded β-
TCP granula (Figure 2B). Th e tissue-engineered construct 
consisting of cells, β-TCP granula, and autologous plasma 
was administered to the necrotic area through a plastic 
funnel (Orthovita Inc.) (Figure 2C,D), and the drill hole 
was sealed with the preserved bony cylinder.
At present, a total of four patients have been treated by 
using the described technique without disease progres-
sion (Figure  3A-D) at the 24-month follow-up. A 
European Union-funded (FP-7) clinical phase I and II 
study is in preparation to evaluate the beneﬁ cial eﬀ ects of 
bone marrow-derived progenitor cell application com-
pared with standard core decompression in the treatment 
of early-stage AVN [21].
Application of allogenic bone marrow-derived stem cells
Th e use of allogenic instead of autologous MSCs for the 
treatment of AVN appears attractive because of logistic 
and economic advantages given that these cells might be 
available as an ‘oﬀ  the shelf ’ product. However, allogenic 
MSCs harbor the danger of disease transmission and 
immunological rejection [22], as observed in organ 
transplantation. Th erefore, a peculiar risk-beneﬁ t analysis 
of allogenic MSC-based strategies in large populations of 
patients has to be addressed, especially when aiming for 
non-life-threatening diseases such as AVN. Because 
Figure 1. Intraoperative fl uoroscopy demonstrating the drilling 
prior to stem cell tricalcium phosphate matrix application. 
(A) A 3-mm K-wire is placed in the anterior portion of the necrosis 
and (B) overdrilled with a 10-mm cannulated drill. (C,D) The same 
procedure is repeated for the posterior part of the necrosis. Reprinted 
with permission from Schattauer [54].
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alternative treatment options are lacking, allogenic MSC 
transplantation appears to be more suitable in severe 
disorders such as osteogenesis imperfecta. Cell engraft-
ment and accelerated growth velocity have been shown 
in children with severe osteogenesis imperfecta after 
systemic administration of isolated allogenic bone 
marrow-derived MSCs [23,24].
Growth factor-based strategies
A variety of growth factors produced by osteogenic cells, 
platelets, and inﬂ ammatory cells – including bone 
morpho genetic proteins (BMPs) [25-27], insulin-like 
growth factor-1 and -2, transforming growth factor-β1 
(TGF-β1), platelet-derived growth factor, and ﬁ broblast 
growth factor-2 – are functionally involved in bone 
healing. Th e bone matrix serves as a reservoir for these 
growth factors, which are activated during matrix resorp-
tion by matrix metalloproteases. Additionally, the acidic 
environment that develops during the inﬂ ammatory 
process leads to activation of latent growth factors, which 
assist in chemo-attraction, migration, proliferation, and 
diﬀ erentiation of MSCs into osteoblasts or chondroblasts 
[25-27]. All of these functions are driven by complex 
interactions among growth factors and other cytokines 
and are inﬂ uenced by multiple regulatory factors. Th us, 
the use of osteogenic growth or diﬀ erentiation factors for 
joint-preserving treatment of AVN is also a potentially 
promising approach [28].
Osteogenic growth factors
Bone morphogenetic proteins
Healing of osseous tissue is regulated mainly by members 
of the TGF-β superfamily. Speciﬁ cally, BMPs act to 
induce the formation of both bone and cartilage by 
stimulating mesenchymal progenitor cells. However, only 
a subset of BMPs, notably BMP-2, -4, -7, and -9, have 
been shown to exhibit osteoinductive activity in de novo 
bone formation [25-28]. Lieberman and colleagues [29] 
treated 15 patients (17 hip joints at Ficat stage II or III) 
after core decompression with allogenic, antigen-ex-
tracted, autolyzed ﬁ bula grafts, combined with 50 mg of 
recombinant human BMP-2 and non-collagenous protein. 
During the mean follow-up of 53 months, three patients 
(one Ficat stage II and two Ficat stage III) required total 
hip replacement because of an aggravation of clinical 
symptoms corresponding with radiographic progression 
[29].
Mont and colleagues [30] aug mented bony defects 
result ing from AVN with a triphasic bone substitute 
consisting of DBM, processed allograft bone chips, and a 
thermoplastic carrier plus the addition of BMP-7 in 19 
patients (21 hip joints). Eighty-six percent of the treated 
hips were assessed as positive outcomes  – Harris Hip 
Figure 2. Preparation and application of the stem cell 
tricalcium phosphate (TCP) matrix. (A) The stem cell suspension 
is applied to the β-TCP granula. (B) This is followed by the addition 
of intraoperatively obtained autologous serum. (C,D) The matrix 
is transplanted without compression by using a push rod and a 
custom-made funnel-shaped applicator. Reprinted with permission 
from Schattauer [54].
Figure 3. Postoperative radiographs of a 38-year-old patient 
with avascular necrosis (ARCO stage II) of the right hip. 
(A) Postoperative x-ray. X-rays of the right hip joint at 6 months 
(B), 12 months (C), and 24 months (D) after treatment. Over time, 
the sclerotic and necrotic zones have decreased in size, especially 
on the lateral side. Despite the extensive defect, the femoral head 
has neither collapsed nor progressed to an ARCO stage III. After 
24 months, the beta-tricalcium phosphate (β-TCP) granula have not 
undergone complete resorption. Reprinted with permission from 
Schattauer [54]. ARCO, Association Research Circulation Osseous.
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Score (HHS) of at least 80 – at the ﬁ nal follow-up (mean 
follow-up of 48 months) [30]. Th e same group conducted 
a retrospective cohort study in 33 patients (39 hip joints: 
22 at Ficat stage II and 17 at Ficat stage III) implanted 
with autologous, non-vascularized bone grafts loaded 
with BMP-7. At the ﬁ nal follow-up (mean of 36 months), 
only four out of 22 Ficat stage II hips and 11 out of 17 
Ficat stage III hips had undergone hip arthroplasty. At 
present, whether the administration of BMPs results in 
better clinical out comes remains unclear as the literature 
lacks controlled randomized studies that include 
appropriate numbers of patients and control groups [31].
In another study, Mont and colleagues [32] created an 
experimental bony defect at the antero-lateral aspect of 
the femoral head in canines. Th e defect was augmented 
with an autologous bone graft from the iliac crest in 
combination with 250  mg of BMP-7 per gram of auto-
graft. In the control group, the defect remained un-
treated. Four months after surgery, all control animals 
showed a collapse of the femoral head with degeneration 
of the hyaline cartilage. Autograft augmentation with or 
without BMP-7 preserved the subchondral bone and the 
production of a surface layer of hyaline cartilage. Inde-
pen dently of BMP supplementation, radiographs revealed 
good to excellent osseous remodeling when autograft 
augmentation was performed [32].
Th e healing potential of BMP-2- and BMP-14-loaded 
collagen scaﬀ olds was investigated by Simank and 
colleagues [33] in a sheep model. Necrosis of the femoral 
head was created by direct ethanol injection. After core 
decompression, BMP-laden scaﬀ olds were transplanted 
and compared with non-loaded scaﬀ olds. Th ree months 
after surgery, both growth factor-treated groups revealed 
better bone regeneration histomorphologically [33]. 
When the same animal model was used, BMP-14-loaded, 
hydroxyapatite-coated collagen scaﬀ olds (Healos; DePuy, 
Warsaw, IN, USA) signiﬁ cantly improved bony remodel-
ing of the necrotic area. In comparison, when the scaﬀ old 
was applied without BMP-14, only partial defect ﬁ lling 
with mainly ﬁ brous tissue and persistence of the necrosis 
was seen after 12 weeks [34].
To achieve long-term availability of osteoinductive or 
angiogenic growth factors in a defect, it is also possible to 
deliver gene-modiﬁ ed cells synthesizing and secreting 
the desired protein. Genetic engineering strategies focus-
ing on osteoinductive factors have emerged as eﬃ  cient 
approaches to enhance bone formation. Two modalities 
are generally used: (a) direct in vivo delivery of gene 
constructs and (b) ex vivo transduction and subsequent 
transplantation of cells expressing the osteoinductive 
factor [4]. Th e choice of the gene delivery method 
depends on several factors, including the particular gene 
of interest, indication targeted, desired duration of gene 
expression, and nature of the delivery vector.
Tang and colleagues [35] induced bilateral AVN in 
goats by ligation of the lateral and medial circumﬂ exing 
arteries and additional delivery of liquid nitrogen to the 
femoral head. Th e authors investigated the inﬂ uence of 
MSCs, transduced with either BMP-2 or β-galactosidase 
and seeded onto β-TCP scaﬀ olds on AVN consolidation. 
Th ree weeks after core decompression, the tissue-
engineered constructs were transplanted. Whereas control 
animals (core decompression only) showed AVN progres-
sion with structural disintegration and collapse of the 
subchondral bone 4 months after treatment, no signs of 
such progression were observed in the cell-treated groups 
[35]. In the case of BMP-2 transduction, superior bone 
regeneration in the defects was observed when compared 
with the β-galactosidase group, as were signiﬁ cantly 
higher amounts of new bone and higher maximum 
compressive strength and bone density [35].
Angiogenic growth factors
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) regulates 
numerous cellular events associated with angiogenesis 
and vasculogenesis, such as tissue remodeling, during 
embryonic development and in adults [36]. Yang and 
colleagues [37] delivered plasmids encoding VEGF 
immobi lized on a collagen carrier into the necrotic area 
of the femoral head in rabbits. Signiﬁ cantly higher bone 
formation was reported 8 weeks after treatment in com-
parison with control animals that received a collagen 
carrier without VEGF plasmids. Th e successful in vivo 
transfection of local cells by the VEGF plasmids and 
expression of VEGF after surgical delivery, however, were 
shown up to 2 weeks only [37].
Other growth factors
Granulocyte colony-stimulating factor and stem cell factor
Granulocyte colony-stimulating factor (G-CSF) is a glyco-
protein, growth factor, and cytokine with two isoforms, 
both of which stimulate the proliferation of bone marrow 
stromal cells and enhance their availability in the circulat-
ing blood volume [38]. Stem cell factor (SCF) is a cyto-
kine that plays a critical role in regulating the diﬀ eren-
tiation of hematopoietic stem cells. After intramuscular 
application of G-CSF and SCF, Wu and colleagues [39] 
observed increased blood vessel formation (3.3-fold), a 
higher blood vessel density (2.6-fold), and increased bone 
formation in the necrotic area of steroid-induced AVN of 
rabbits in comparison with a non-treated control group. 
However, whether direct angiogenic/osteogenic diﬀ eren-
tiation of the mobi lized progenitor cells accounted for 
the increased vascularization and bone formation or 
whether an increased trophic activity of these cells 
activated endogenous progenitor cells at the defect site 
was unclear [39].
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Hepatocyte growth factor
Hepatocyte growth factor (HGF) is a multifunctional 
cyto kine that regulates cell growth, cell motility, and 
morphogenesis and exhibits synergistic eﬀ ects with 
VEGF [40]. Wen and colleagues [41] used a hormone-
induced AVN rabbit model to compare the therapeutic 
eﬀ ect of core decompression alone versus the additional 
augmentation of the necrotic area with HGF-transduced 
MSCs administered in ﬁ brin glue. De novo bone forma-
tion with regular trabecular structure and enhanced 
vascularization of the necrotic bone was observed only in 
animals treated with HGF-transduced MSCs as shown by 
magnetic resonance imaging and computed tomography 
imaging and immunohistochemistry [41].
Anterograde osteochondral reconstruction in 
advanced stages of avascular necrosis
With the progression of untreated AVN (ARCO stage III 
and IV), structural disintegration of the subchondral 
bone occurs and leads to the collapse of the femoral head. 
A substantial degeneration of the hyaline cartilage has to 
be assumed at this stage, and retrograde strategies, such 
as core decompression and autologous bone grafting, 
oﬀ er only very limited prospects [42]. In most of these 
cases, total joint replacement remains the only treatment 
option [43]. Th e potential of regenerative, joint-preser v-
ing techniques, such as osteochondral trans plantation 
(auto grafts or allografts), bone grafting followed by 
autologous chondrocyte implantation (ACI), or acellular 
matrix implantation, has not been exploited suﬃ  ciently 
so far. Th ese techniques include a surgical dislocation of 
the hip to anterogradely access the osteochondral defect, 
which is more invasive and surgically demanding [42,44].
Osteochondral transplantation (mosaicplasty)
Meyers and colleagues [45,46] trans planted osteochon dral 
autografts or allografts in 21 patients with pro gressed 
stages of AVN (Ficat stage II to IV) after hip dislocation 
and debridement of the osteo chondral defect. Th e 
treatment was reported to be successful in 71% to 80% of 
all cases (follow-up for 1.5 to 5 years) but in only 50% of 
the patients with steroid-induced AVN [45,46]. Sotereanos 
and colleagues [47] treated a 36-year-old patient after 
ineﬀ ective core decom pression and vas cular ized ﬁ bula 
graft augmentation. Th ree osteochondral cylinders were 
transferred from a non-weight-bearing area at the inferior-
lateral femoral head into the defect following bone 
grafting. After 5  years, the HHS was 96, the patient was 
pain-free, and the range of motion was not limited [47].
Rittmeister and colleagues [48] performed an autolo-
gous osteochondral transfer (one to three grafts) in ﬁ ve 
patients with advanced AVN. After a mean follow-up of 
57  months, the therapy failed in four patients and total 
hip arthroplasty was required. Only one patient was 
treated successfully, and hip function showed no limita-
tions 31 months after surgery [48].
Autologous chondrocyte implantation
ACI has been proven to be a suitable technology for the 
treatment of full-thickness cartilage defects in the knee 
and ankle joint. Its therapeutic potential in the hip has 
not been addressed suﬃ  ciently so far. Only one case 
report on ACI at the femoral head has been published so 
far. Akimau and colleagues [49] treated a 31-year-old man 
with a diagnosed post-traumatic necrosis of the femoral 
head by using a modiﬁ ed ﬁ rst-generation ACI approach. 
Healthy hyaline cartilage (240  mg) was harvested 
arthroscopically from the ipsilateral knee joint, and 
chondrocytes were isolated and expanded in monolayer 
culture over a period of 3 weeks. In a second surgery, the 
femoral head was dislocated and exposed. After removal of 
the degenerated cartilage and necrotic bone, the defect 
was covered with a collagen type I membrane (Chondro-
Gide; Geistlich, Wolhusen, Swit zer land), and 6  ×  106 
chondrocytes were injected underneath the membrane. 
Th e HHS increased from 45 preopera tively to 76 at 12 and 
18 months after surgery. Arthro scopic biopsy revealed a 2 
mm-thick repair tissue consist ing of ﬁ brous and, to a lesser 
extent, hyaline-like cartilage [49].
Acellular matrix implantation
Matrix-based ACI has been shown to be a clinically 
successful method for the treatment of full-thickness 
cartilage defects by using a variety of scaﬀ old materials 
[4,50,51]. In ACI, a previous cartilage biopsy harvest 
followed by ex vivo cell processing, which is time-
consuming and costly, is required. To circumvent these 
barriers, an innovative one-step procedure combining 
micro fractur ing [52] of the subchondral bone and 
coverage of the cartilage defect by using an acellular 
scaﬀ old (Autolo gous Matrix-Induced Chondrogenesis) 
was developed [53]. We recently adopted this basic 
principle for the treatment of an advanced stage of AVN 
in the hip (ARCO stage III) as shown in Figure 4. Th e hip 
joint was dis located after a trochanteric ﬂ ip osteotomy 
was performed [44] and the femoral head was exposed 
(Figure  4). Th e osteochondral defect was debrided, the 
sclerotic bony ground was repeatedly penetrated by using 
a small drill bit, and the bony defect was augmented with 
autologous cancellous bone. Subsequently, the cartilage 
defect was replenished by using an acellular collagen type 
I hydrogel (CaReS-OneStep; Arthro Kinetics, Krems, 
Austria) [54]. So far, three patients have been treated 
with this technique with a follow-up of 9 months.
Conclusions
Core decompression is the gold standard technique for 
the treatment of early-stage AVN of the femoral head 
Rackwitz et al. Stem Cell Research & Therapy 2012, 3:7 
http://stemcellres.com/content/3/1/7
Page 6 of 9
[55-57] and reveals superior clinical outcome in com-
parison with non-operative treatment regimens [58,59]. 
Th e variable and unpredictable clinical outcome led to 
the development of complex surgical techniques, such as 
the transplantation of non-vascularized/vascularized 
autologous bone grafts, aiming [31,60] for a more reliable 
bone regeneration and preservation of a physiological 
joint function. Extensive research activities over the last 
decade explored the potential of mesenchymal progenitor 
cells [4-7] and growth factors [4,5,25,27,28,35,37,54], 
aiming for an autologous ex vivo or in vivo regeneration 
of a variety of musculoskeletal tissues.
Early promising clinical data on the application of 
concentrated bone marrow cells, isolated bone marrow-
derived progenitor cells, and growth factors for the 
treatment of AVN have been reported [3,11-15,31,32]. 
However, so far, both cell- and growth factor-based 
strategies undertaken lacked randomized clinical trials to 
suﬃ  ciently validate their eﬃ  ciency in comparison with 
conventional therapies. Whether and to what extent the 
observed bone regeneration resulted from the applied 
cells or growth factors remain uncertain.
In addition, ex vivo processed/expanded cells are classi-
ﬁ ed as advanced therapy medicinal products (ATMPs) by 
the competent international and national regulatory 
agencies (for example, the FDA and the EMA). ATMPs 
have to fulﬁ ll speciﬁ c quality and safety criteria that rely 
on standardized GMP conditions for cell processing, the 
performance of adequate preclinical animal models for 
the targeted disease, and controlled clinical phase I/II 
trials [16]. Th is increases time- and cost-consuming 
barriers on the way to FDA/EMA approval on the one 
hand but provides the opportunity to investigate the 
potential of cell-based strategies in musculoskeletal 
diseases guided by a controlled regulatory framework on 
the other hand. Also, owing to unresolved safety con-
cerns, the clinical translation of gene therapy approaches 
for the treatment of AVN is currently not feasible at all.
Th e treatment of osteochondral defects in advanced 
stages of AVN, characterized by a collapse of the sub-
chondral bone, remains an unresolved burden in 
orthopedic surgery [1-3]. As a result, the predominantly 
young patients usually require total hip arthroplasty 
[2,3,61]. At present, the applicability of regenerative 
joint-preserving techniques, such as matrix-based ACI or 
osteochondral transplantation, has not been adequately 
addressed. One reason is likely the technically demanding 
surgical hip dislocation required for anterograde access 
to the femoral head [44].
Applying tissue engineering-based techniques for joint 
preservation approaches could have great therapeutic 
potential in the restoration of femoral head integrity 
[4,28,54]. It is noteworthy that the few case reports 
recently published have shown heterogeneous results, 
ranging from complete therapeutic failure to full recovery 
with restored hip function [45-49]. Full evaluation of the 
promising therapeutic potential of these novel regenera-
tive strategies for AVN will require rigorous randomized 
controlled trials that address stage-dependent treatment 
of the disease.
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